Effect of Re-education on Rebleeding Rate After Endoscopic Treatment in Liver Cirrhosis
NCT ID: NCT05302661
Last Updated: 2022-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
508 participants
INTERVENTIONAL
2022-02-19
2024-02-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism
NCT05055713
The Effects of Early Enteral Nutrition on Endoscopic Therapy of Esophagogastric Varices in Liver Cirrhosis
NCT04823780
The Timing of Emergency Endoscopy for Esophagogastric Variceal Bleeding in Cirrhosis
NCT04932200
Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis
NCT02335580
Timing of Endoscopy for Acute Variceal Bleeding in Patients With Cirrhosis
NCT04957875
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
case group will receive re-education after leave hospital
The participants were randomly divided into re-education group and non re-education group according to the random number table. The re-education group will receive regular re-education not noly when they leave hospital but also after leave hospital in our preset time by telephone or wechat. The content of re-education includes diet form and diet structure,medication compliance and regularity, and recheck compliance, moderate exercise and so on
re-education
Contact patients by phone or wechat and guide them
control case group will receive no re-education after leave hospital
The participants were randomly divided into re-education group and non re-education group according to the random number table. without re-education group will receive regular re-education when they leave hospital.The content of re-education includes diet form and diet structure,medication compliance and regularity, and recheck compliance, moderate exercise and so on
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
re-education
Contact patients by phone or wechat and guide them
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* liver cirrhosis ;
* patients receiving endoscopic treatment (esophagogastric variceal sclerosis and/or ligation) ;
* All subjects or their guardians must sign the subject consent form before entering the test
Exclusion Criteria
* ASA score ≥ grade IV at discharge ;
* Hepatic encephalopathy ≥ stage II;
* Patients with liver cancer;
* Pregnant and lactating women;
* Patients who cannot sign informed consent
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qilu Hospital of Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yanjing Gao, MD
Role: PRINCIPAL_INVESTIGATOR
Qilu Hospital, Shandong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qilu Hospital
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20211013-Li
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.